Answers are grounded in this paper and cite their sources.
Case report reveals Addisonian crisis following zoledronic acid therapy in adrenal insufficiency, suggesting monitoring needs.
Addisonian crisis secondary to parenteral therapy with zoledronic acid has been rarely reported in the literature. The case report herein presents a case of a 27-year-old female patient with a known history of panhypopituitarism and secondary adrenal insufficiency who developed an Addisonian crisis following her first intravenous infusion of zoledronic acid. This highlighted the role of zoledronic acid as a potential trigger. This is probably mediated by an acute-phase reaction with the lack of a sufficient cortisol response. Therefore, close monitoring of patients with adrenal insufficiency undergoing osteoprotective therapy, at least during the first administration, is indeed recommended.
No takes yet. Share an insight, caveat, or question.
Nour et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: